Please login to the form below

Not currently logged in
Email:
Password:

Zelboraf

This page shows the latest Zelboraf news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma

Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients.

Latest news

More from news
Approximately 10 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    For example, skin cancer patients who carry a BRAF V600 mutation are more likely to respond to BRAF inhibitors like Roche’s Zelboraf (Vemurafenib) than people without such mutations.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie

  • Pharma deals during April 2014 Pharma deals during April 2014

    Indeed a whopping $1.5bn payment depends on the results of the on-going combination trial against Roche's Zelboraf.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

  • Kite Pharma appoints Zelboraf scientist as CMO Kite Pharma appoints Zelboraf scientist as CMO

    Keith Nolop joins US cancer biotech from Plexxikon. Dr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief ... During this time, he was clinical lead for the

  • AstraZeneca hires Roche’s Pascal Soriot as CEO

    This merger has spawned such drugs as cancer treatments Avastin, Herceptin and Zelboraf, and is deemed to be one of the more successful pharma deals of recent years, while during that

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics